Bio-Techne
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Bio-Techne and other ETFs, options, and stocks.About TECH
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Its products assist scientific investigations into biological processes and the nature and progress of specific diseases.
TECH Key Statistics
Stock Snapshot
As of today, Bio-Techne(TECH) shares are valued at $57.41. The company's market cap stands at 8.95B, with a P/E ratio of 117.35 and a dividend yield of 55.7%.
As of 2025-11-08, Bio-Techne(TECH) stock has fluctuated between $56.58 and $58.04. The current price stands at $57.41, placing the stock +1.5% above today's low and -1.1% off the high.
The Bio-Techne(TECH)'s current trading volume is 1.69M, compared to an average daily volume of 2.15M.
In the last year, Bio-Techne(TECH) shares hit a 52-week high of $79.28 and a 52-week low of $46.01.
In the last year, Bio-Techne(TECH) shares hit a 52-week high of $79.28 and a 52-week low of $46.01.
TECH News
Bio-Techne (TECH) reported net profit margins shrinking to 6% due to a significant one-off loss of $164.1 million. This is down from 14.5% a year ago. Over the...
Bio-Techne ((TECH)) has held its Q1 earnings call. Read on for the main highlights of the call. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst c...
In afternoon trading on Wednesday, Healthcare stocks are the worst performing sector, showing a 2.3% loss. Within that group, Moderna Inc (Symbol: MRNA) and Bio...
Analyst ratings
74%
of 19 ratingsMore TECH News
Earnings Call Insights Bio-Techne outlines temporary cell therapy headwinds and expects low single-digit FY26 growth while margin expands Nov. 05, 2025 1:12 PM...
(RTTNews) - Bio-Techne Corp. (TECH) reported a profit for its first quarter that Increases, from the same period last year in line with the Street estimates. T...
Reports Q1 revenue $286.56M, consensus $291.34M. “The Bio-Techne (TECH) team once again executed with focus and agility in a dynamic operating environment,” sai...
Bio-Techne (TECH) and Nucleai announced the presentation of pivotal data from the SECOMBIT clinical trial at the Society for Immunotherapy of Cancer 2025 Annual...